Latest Janssen Pharmaceuticals Inc. Stories
Xarelto’s low price translates into the lowest out-of-pocket costs to members, according to analysis conducted by the editors of Atlantic Information Services’s new online resource Rx Benefit
TITUSVILLE, N.J., Jan. 15, 2015 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. (JPI) today announced it has entered into a definitive agreement with Depomed, Inc. to divest its U.S.
Findings Add to Rigorous Post-Marketing Safety Program for XARELTO® in Routine Clinical Practice RARITAN, N.J., Jan.
Multidistrict Litigation For Xarelto Bleeding Lawsuits That Allege Patients Experienced Uncontrollable Bleeding And Other Complications After Taking The Prescription Blood Thinner Has Been Established
A Request To Centralize Xarelto Lawsuits Alleging Xarelto Users Experience Uncontrolled Bleeding Due To Taking The Blood Thinner Is Under Consideration By the U.S.
The Firm is representing numerous Risperdal lawsuit plaintiffs who allegedly developed gynecomastia (male breast growth) due to their use of the medication. New
Campaign launches at Washington Redskins' FedExField to raise awareness during a "Tackle Diabetes" gameday takeover RARITAN, N.J., Dec.
The Xarelto Lawsuit Complaint Alleges That Janssen Pharmaceuticals And Bayer HealthCare Did Not Disclose The Bleeding Risks Associated With The Prescription Blood Thinner Medication.
Xarelto Page Launched to Monitor Lawsuits Being Filed on Behalf of Patients Who Allege the Blood Thinner Causes Severe Internal Bleeding and Uncontrollable Bleeding New
The first Risperdal lawsuits trails alleging the anti-psychotic drug caused gynecomastia or enlarged male breasts begin today In Philadelphia. Columbus, OH (PRWEB)